Specialty Drug

CVS Health Acquires Omnicare

Posted on by John Santilli

CVS Health Acquires Omnicare – Well, the guessing game is over as CVS Health acquires Omnicare. The Pharmacy in Long-Term Care market has a new industry leader as CVS Health will see if their business model translates to the long-term care pharmacy market. The LTC market is a different business and CVS is moving from their traditional “core competency”. It […]

Continue reading →
Dr. Randy Vogenberg, Trends

A Call to Action to Address Burden of Unintended Pregnancies in Plans’ Benefit Design

Posted on by John Santilli

Benefit Design – A Call to Action to Address Burden of Unintended Pregnancies in Plans’ Benefit Design F. Randy Vogenberg, PhD, RPh Partner, Access Market Intelligence, Greenville, SC Adjunct Professor of Pharmacy Administration, Presbyterian College School of Pharmacy, Clinton, SC Adjunct Instructor, Outcomes and Health Policy, University of Illinois at Chicago College of Pharmacy Originally […]

Continue reading →
Specialty Drug

Proposed Changes to Rx Information Required in SBC

Posted on by John Santilli

Proposed Changes to Rx Information Required in SBC, Greg Judd, CEBS The American Medical Association (AMA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) are asking regulators to build more information about major medical plan drug coverage into the next revision of the Summary of Benefits and Coverage (SBC) and the Uniform Glossary (LifeHealthPro). […]

Continue reading →
Specialty Drug

Planning a Specialty Drug Strategy Through 2020

Posted on by John Santilli

Planning a Specialty Drug Strategy Through 2020 – Traditional approaches are not suited to managing the cost of specialty drug therapies By Gregory Judd, CEBS, and Randy Vogenberg, PhD  5/4/2015 (originally published by Society for Human Resource Management (SHRM))   The specialty drug tsunami is picking up strength and is about to come crashing down on […]

Continue reading →
Affordable Care Act, Pharmaceutical, Trends

Section 1332 Opportunity for Pharmaceutical Manufacturers

Posted on by John Santilli

Section 1332 Opportunity for Pharmaceutical Manufacturers – by Gregory Judd, CEBS   A funny thing happened while pharmaceutical manufacturers were going through wrenching strategic and organizational changes during the past 6 or 7 years. The Affordable Care Act. Ok, so ACA is not all THAT funny. But it IS big, and has exerted a sort of […]

Continue reading →
Pharmaceutical, Trends

Pharmaceutical Growth Driven by M&A and Shareholder Value

Posted on by John Santilli
28
Apr

Pharmaceutical Growth Driven by M&A and Shareholder Value – Biologic and Pharmaceutical companies, along with their financial advisors or venture capital partners, have used mergers and acquisitions over the years to create value in order to keep their leading positions in a changing market. The era of pharmaceutical companies relying on blockbusters for their growth […]

Continue reading →
Dr. Randy Vogenberg

Seeking Value: Managing Specialty Medications and Medication Adherence

Posted on by John Santilli

Amid the constant change churning the health care marketplace, employers have the opportunity to use value-based tactics to get more for their health benefits, including pharmaceutical spending that is currently the biggest driver of rising health care costs. That message was echoed by all four speakers at the Alliance Learning Circle on “Doses and Dollars: […]

Continue reading →
Affordable Care Act, Dr. Randy Vogenberg, John Santilli, Market Intelligence, Trends

Key Strategic Trends that Impact Healthcare Decision-Making and Stakeholder Roles in the New Marketplace

Posted on by aprilgregory

By John Santilli, MBA, and F. Randy Vogenberg, PhD, RPh After the passage of the Affordable Care Act (ACA) in 2010, market changes beyond those already in play began to emerge. Traditional roles, responsibilities, and authority could now be tested or altered as a result of some sections of the ACA. One result is that […]

Continue reading →